Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pyrotinib, trastuzumab, paclitaxel-albumin
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.